Therapeutic Asset Ratings

3,272 results matching 1 filter

91,565 assets7,904 sponsors3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Elimusertib Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P1/2	CC (45)
Entinostat Renal Carcinoma	National Cancer Institute (NCI)	P1/2	CC (45)
Entinostat Penile Cancer	National Cancer Institute (NCI)	P1/2	CC (45)
Iadademstat Lung Cancer	National Cancer Institute (NCI)	P1/2	CC (45)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Colorectal Adenocarcinoma	National Cancer Institute (NCI)	P1/2	CC (45)
Inqovi Myelodysplastic Syndrome	National Cancer Institute (NCI)	P1/2	CC (45)
Methoxyamine Refractory Malignant Neoplasm	National Cancer Institute (NCI)	P1/2	CC (45)
Navitoclax Cutaneous Melanoma	National Cancer Institute (NCI)	P1/2	CC (45)
Navitoclax Cancer	National Cancer Institute (NCI)	P1/2	CC (45)
pds01adc Penile Cancer	National Cancer Institute (NCI)	P1/2	CC (45)
Pidnarulex Burkitt Lymphoma	National Cancer Institute (NCI)	P1/2	CC (45)
Pidnarulex High Grade B-Cell Lymphoma With MYC And/ Or BCL2 And/Or BCL6 Rearrangement	National Cancer Institute (NCI)	P1/2	CC (45)
Pidnarulex Colorectal Adenocarcinoma	National Cancer Institute (NCI)	P1/2	CC (45)
SX682 Nasopharyngeal Carcinoma	National Cancer Institute (NCI)	P1/2	CC (45)
Tiragolumab Cancer	National Cancer Institute (NCI)	P1/2	CC (45)
Trastuzumab Deruxtecan Pancreatic Ductal Adenocarcinoma	National Cancer Institute (NCI)	P1/2	CC (45)
Tuvusertib Hematopoietic And Lymphoid System Neoplasm	National Cancer Institute (NCI)	P1/2	CC (45)
Veliparib Lung Adenocarcinoma	National Cancer Institute (NCI)	P1/2	CC (45)
Adavosertib Melanoma	National Cancer Institute (NCI)	P2	CC (44)
Copanlisib Colorectal Carcinoma	National Cancer Institute (NCI)	P2	CC (44)
Copanlisib Glioma	National Cancer Institute (NCI)	P2	CC (44)
Fluoromisonidazole Pancreatic Adenocarcinoma	National Cancer Institute (NCI)	P2	CC (44)
Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, Dimer ALK-Positive Large B-Cell Lymphoma	National Cancer Institute (NCI)	P2	CC (44)
Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, Dimer Diffuse Large B-Cell Lymphoma Activated B-Cell Type	National Cancer Institute (NCI)	P2	CC (44)
Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, Dimer Diffuse Large B-Cell Lymphoma With Chronic Inflammation	National Cancer Institute (NCI)	P2	CC (44)

Showing 2601 to 2625 of 3,272 assets

PreviousPage 105 of 131Next